NCT00881322已完成不适用
A Prospective, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Clinical Trial to Evaluate the Effects of Gas Defense On Intestinal Gas Symptoms in Otherwise Healthy Adults
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 61
- 试验地点
- 3
- 主要终点
- To determine the effect of daily supplementation with GD as compared to placebo on intestinal gas symptoms as measured by the subscores of the GI Symptom Rating Scale (GSRS) and the subscores of the Severity of Dyspepsia Assessment (SODA).
研究概览
简要总结
This is a randomized, double-blind, placebo-controlled trial to determine the safety and efficacy of Digestive Advantage™ Gas Defense formula, a probiotic dietary supplement. The study will last approximately four weeks, and subjects will be seen at a screening/randomization visit, and two follow-up visits.
Study procedures will include administering questionnaires for assessment of the study product's effect on intestinal gas symptoms and quality of life.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subject is 18-75 years of age.
- •Subject self-reports at least one of the following symptoms after eating a meal or snack:
- •Abdominal pain/cramps
- •Distended feeling/bloating
- •Flatulence/gas
- •Subject is in otherwise general good health as determined by physical exam and medical history.
- •Subject is willing and able to comply with the protocol.
- •Female subjects not defined as post-menopausal (excluding hysterectomized and post bilateral tubal ligations) must use a reliable method of birth control as defined within this protocol.
- •Subject is able to understand and sign the informed consent (English or Spanish) to participate in the study.
排除标准
- •Subject has any of the following medical conditions:
- •active heart disease
- •renal or hepatic impairment/disease
- •Type I or II diabetes
- •psychiatric disorders (hospitalized within the past one year)
- •bipolar disorder
- •Parkinson's disease
- •unstable thyroid disease
- •immune disorder (such as HIV/AIDS)
- •any medical condition deemed exclusionary by the Principal Investigator (PI)
- •Subject has a history of cancer (except localized skin cancer without metastases or in situ cervical cancer) within five years prior to screening.
- •Subject has had any stomach or intestinal surgery (i.e. gastric bypass).
- •Subject is currently taking antibiotics (or any drug that significantly interferes with bacterial flora) or has taken antibiotics within the 30 days prior to screening/enrollment.
- •Subject is currently taking or has used in the past 30 days probiotics or prebiotics.
- •Subject is on an unstable dose of medication (defined as fewer than 90 days at the same dose).
- •Subject is currently taking any medication deemed exclusionary by PI.
- •Subject has a history of or currently has any gastrointestinal disorders or inflammatory bowel conditions such as Crohn's disease, short bowel, or ulcerative colitis. Subjects may not have a diagnosis, be seeing a doctor, or taking prescription medication(s) for Irritable Bowel Syndrome (IBS).
- •Subject has constipation defined as less than three spontaneous bowel movements per week.
- •Subject is lactose intolerant (self-professed or diagnosed).
- •Subject uses any of the following classification of GI medications two or more times per week: anti-spasmodics, motility agents, pro-kinetic agents or laxatives.
- •Subject plans to use another over-the-counter gas-relief product daily during the study period. Over-the-counter gas relief products may be used as rescue medication (their use will be captured by the study staff). If a subject is using a fiber supplement prior to starting the study, he/she may continue as long as the frequency and quantity remain stable throughout the study period.
- •Subject has an allergy to wheat or fish or any of the other product ingredients (see section 2.5.4).
- •Subject has two or more food allergies.
- •Subject has a history of drug or alcohol abuse within the past 12 months.
- •Subject is deemed by the Investigator as an unsuitable candidate for receipt of an investigational dietary supplement, or unable to be followed up throughout the entire duration of the study.
- •Female subject of childbearing potential is unwilling to use an acceptable form of contraceptive device throughout the study period.
- •Subject is pregnant, lactating, or planning to become pregnant during the study period.
- •Subject is participating in another clinical trial or has received an investigational product within 30 days prior to screening/enrollment.
- •Subject is deemed by the Investigator as an unsuitable candidate for receipt of an investigational dietary supplement, or unable to be followed up throughout the entire duration of the study.
- •Subject is unable to comprehend the Informed Consent and research purpose.
- •Subject is unable or unwilling to comply with the protocol.
结局指标
主要结局
To determine the effect of daily supplementation with GD as compared to placebo on intestinal gas symptoms as measured by the subscores of the GI Symptom Rating Scale (GSRS) and the subscores of the Severity of Dyspepsia Assessment (SODA).
时间窗: 4 weeks
Primary Safety Objective To determine if daily supplementation with GD is safe within the confines of this study as denoted by changes from baseline in blood pressure, heart rate, adverse events, and subjective remarks.
时间窗: 4 weeks
次要结局
未报告次要终点
研究者
研究点 (3)
Loading locations...
相似试验
已完成
3 期
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's DiseaseCrohn's DiseaseNCT01277666GlaxoSmithKline608
已完成
2 期
Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes MellitusType1 Diabetes MellitusNCT03117998REMD Biotherapeutics, Inc.154
已完成
不适用
A Clinical Trial to Evaluate the Efficacy and Safety of MXP22 on Liver HealthNon-Alcoholic Fatty Liver DiseaseNCT05808049Vedic Lifesciences Pvt. Ltd.60
已完成
3 期
Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) PatientsPhenylketonuriaNCT01114737BioMarin Pharmaceutical206
已完成
2 期
Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract InfectionsAcute PyelonephritisComplicated Urinary Tract InfectionNCT03445195Entasis Therapeutics80